



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : R. Vanlalsiama, (Asst. Director (F and D))
CMO Office, Lunglei.
2. Serial No. and date of Inspector's memorandum : 8 , 23-JAN-2026
3. Number of Sample : MS-1
4. Date of receipt : 25-FEB-2026
5. Names of drugs purporting to be contained in the sample : Atorvastatin Tablets IP 20 mg

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2026-27/0051	GUW/LS/2026-27/37	C21G535005	May-2025 Apr-2027	NA	Concept Pharmaceuticals Ltd., A-28/3, MIDC, Chikalthana, Aurangabad - 431 006

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 22-Apr-2026 To 23-Apr-2026

COMPOSITION : Each film coated tablet contains : Atrovastatin calcium IP Eq. to Atrovastatin 20 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Yellow colored, round shaped, bi-convex, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Atrovastatin calcium.	NA
3	Average weight	0.2062 g	NA
4	Test for Dissolution	Complies.	NLT 70 % of Claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method

1	Atorvastatin Calcium equivalent to Atorvastatin	21.62 mg/Tablet	20 mg/Tablet	108.1	90 % to 110 %	I.P. 2022
---	---	-----------------	-----------------	-------	---------------	-----------

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 27-APR-2026

GOVERNMENT ANALYST

Rinku Kalita
Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----

